Back to All

Summary of non-regulatory news and coverage for Q4, 2020

21 January, 2021

Diaceutics PLC (AIM: DXRX) provides an overview to the market for Q4 2020. The Company would like to issue an update of non-regulatory news and coverage that has been achieved in the last quarter of 2020 in order to keep investors abreast of the Company’s activities. This announcement contains a summary of key media mentions and links to original pieces with examples, along with some supporting highlights.

The launch of DXRX – The Diagnostic Network® has been very successful, and Diaceutics cited 557 mentions* in the news during Q4 with the launch of the platform.

Examples include Bloomberg: https://www.bloomberg.com/press-releases/2020-10-01/19-organizations-from-the-healthcare-community-unite-to-form-covid-19-testing-industry-consortium

Examples include Proactive Investors: https://www.proactiveinvestors.co.uk/companies/news/934161/hybridan-small-cap-feast---afc-energy-bahamas-petroleum-altus-strategies-and-others-934161.html

Peter Keeling

Peter Keeling, CEO of Diaceutics commented:We are pleased to provide a comprehensive update to the market on all the news and activity we have had that has not been issued through the regulatory channels in the last quarter of 2020. Sometimes when focusing purely on our RNS newsfeed, other media activity can be missed and we feel it is important to give our valued investors and potential new shareholders the opportunity to see a cross section of other items we have released and the outcomes of those announcements for their perusal. As a business, we are fortunate to be performing well against the backdrop of the pandemic affecting the global economy and we are glad to be able to share evidence of this activity. 

“Going forward, we will be issuing a similar update quarterly and hope to have more key achievements as we move through the year. The next statement will be due following the completion of Q1, in April 2021.” 

 *source – Meltwater

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.